Home Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study
Article
Licensed
Unlicensed Requires Authentication

Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study

  • Lutz Schwettmann , Wolf-Rüdiger Külpmann and Christian Vidal
Published/Copyright: September 21, 2011

Abstract

Two commercially available drug-screening assays were evaluated: the Roche kinetic interaction of microparticles in solution (KIMS) assay and the Microgenics cloned enzyme donor immunoassay (CEDIA). Urine samples from known drug-abuse patients were analyzed for amphetamines, barbiturates, benzodiazepines, benzoylecgonine, cannabinoids, LSD, methadone and opiates. Samples with discordant findings for the two assays were analyzed by gas chromatography/mass spectrometry (GC/MS) or gas chromatography/electron capture detection (GC/ECD). Amphetamines showed 96.0% concordant results, with two false positive findings by CEDIA, three by KIMS and a further two false negatives by KIMS. Barbiturates showed 99.4% concordant results, with one false negative by KIMS. Benzodiazepines showed 97.4% concordant results, with two false negatives by KIMS (cutoff 100μg/L, CEDIA cutoff 300 μg/L). Benzoylecgonine showed 17.8% concordant positive and 82.2% concordant negative results and no false finding by either assay. Cannabinoids showed 99.3% concordant results, with one sample negative by KIMS at a cutoff of 50μg/L and positive by CEDIA (cutoff 25μg/L). For LSD, 6.7% of findings were not in agreement. Methadone showed 97.5% concordant results, with two false positives by CEDIA, and one false positive and one false negative by KIMS. Opiates showed 96.9% concordant results, with no false KIMS results, but four false positives by CEDIA. The results indicate that the agreement of the CEDIA and KIMS results for the eight drugs is rather good (93.3–100%).


Corresponding author: W.R. Külpmann, Medizinische Hochschule Hannover, Klinische Chemie, Carl-Neuberg-Str.1, 30625 Hannover, Germany Phone: +49-511-5326614, Fax: +49-511-5325671

References

1. Yasui-Furukori N, Saito M, Furukori H, Inoue Y, Someya T, Kaneko S, et al. Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol. Ther Drug Monit 2004; 26:336–41.10.1097/00007691-200406000-00020Search in Google Scholar PubMed

2. Jenkins AJ, Lavins ES, Snyder A. Evaluation of the CEDIA heroin metabolite (6-AM) immunoassay with urine specimens from criminal justice drug-testing program. J Anal Toxicol 2005; 28:201–4.10.1093/jat/29.3.201Search in Google Scholar PubMed

3. Klette KL, Wiegand RF, Horn CK, Stout PR, Magluilo J. Urine benzodiazepine screening using Roche online KIMS immunoassay with β-glucuronidase hydrolysis and confirmation by gas chromatography-mass spectrometry. J Anal Toxicol 2005; 29:193–200.10.1093/jat/29.3.193Search in Google Scholar PubMed

4. Kroener L, Musshoff F, Madea B. Evaluation of immunochemical drug screening of whole blood samples. A retrospective optimization of cutoff levels after confirmation analysis on GC-MS and HPLC-DAD. J Anal Toxicol 2003; 27:205–12.10.1093/jat/27.4.205Search in Google Scholar PubMed

5. Roche Diagnostics. Technical package insert for Cobas Integra barbiturates assay, May 2004.Search in Google Scholar

6. Feldman M, Kuntz D, Botelho K, Ananias DC, Gnezda M, Hoch DK, et al. Evaluation of Roche Diagnostics Online DAT II, a new generation of assays for the detection of drugs of abuse. J Anal Toxicol 2004; 28:593–8.10.1093/jat/28.7.593Search in Google Scholar PubMed

7. Huestis MA, Mitchell JM, Cone EJ. Lowering the federally mandated cannabinoid immunoassay cutoff increases true-positive results. Clin Chem 1994; 40:304–6.10.1093/clinchem/40.5.729Search in Google Scholar

8. Külpmann WR. Drug screening: actual status, pitfalls and suggestions for improvement. J Lab Med 2004; 28:317–25.Search in Google Scholar

Received: 2005-11-17
Accepted: 2006-1-15
Published Online: 2011-9-21
Published in Print: 2006-4-1

©2006 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Natriuretic peptides and evidence-based quality specifications
  2. Preanalytical variability: the dark side of the moon in laboratory testing
  3. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay
  4. Hepatorenal syndrome
  5. Modified Levey-Jennings charts for calculated laboratory tests
  6. Increased free malondialdehyde concentrations in smokers normalise with a mixed fruit and vegetable juice concentrate: a pilot study
  7. The exponentially weighted moving average (EWMA) rule compared with traditionally used quality control rules
  8. Intermethod calibration of alanine aminotransferase (ALT) and γ-glutamyltransferase (GGT) results: application to Fibrotest® and Actitest® scores
  9. Comparison of TEST 1 with SRS 100 and ICSH reference method for the measurement of the length of sedimentation reaction in blood
  10. Multicenter evaluation of the interference of hemoglobin, bilirubin and lipids on Synchron LX-20 assays
  11. Technical evaluation of the Beckman Coulter OV-Monitor (CA 125 antigen) immunoassay
  12. Erythrocyte membrane Na+,K+-ATPase and Mg2+-ATPase activities in subjects with methylenetetrahydrofolate reductase (MTHFR) 677 C→T genotype and moderate hyperhomocysteinaemia. The role of L-phenylalanine and L-alanine
  13. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes
  14. Pyrosequencing protocol requiring a unique biotinylated primer
  15. Detection of antibodies against 60-, 65- and 70-kDa heat shock proteins in paediatric patients with various disorders using Western blotting and ELISA
  16. Quantitative determination of erythrocyte folate vitamer distribution by liquid chromatography-tandem mass spectrometry
  17. Time-level relationship between indicators of oxidative stress and Glasgow Coma Scale scores of severe head injury patients
  18. Stepwise strategies in analysing haematuria and leukocyturia in screening
  19. Elevation of serum cerebral injury markers correlates with serum choline decline after coronary artery bypass grafting surgery
  20. Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study
  21. Release of anandamide from blood cells
  22. Rapid decrease in plasma D-lactate as an early potential predictor of diminished 28-day mortality in critically ill septic shock patients
  23. Evaluation of an immunoassay of whole blood sirolimus in pediatric transplant patients in comparison with high-performance liquid chromatography/tandem mass spectrometry
  24. Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases
  25. Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens
  26. Importance of the functional sensitivity determination of a serum hyaluronic acid assay for the prediction of liver fibrosis in patients with features of the metabolic syndrome
  27. The dilemma of invasive and non-invasive investigations for adult and paediatric non-alcoholic fatty liver disease: has the time come for a new biochemical marker?
  28. Is cystatin C a reliable renal marker in trauma?
  29. On the independence of intraindividual reference values
  30. Sixth International Symposium on Molecular Diagnostics, Graz, Austria, May 25-27, 2006
Downloaded on 14.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2006.087/html
Scroll to top button